At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNTM Quantum Biopharma Ltd.
Trading 10-15 09:53:04 EDT
2.73
+0.07
+2.68%
High2.74Low2.65Vol12.12K
Open2.65D1 Closing2.66Amplitude3.38%
Mkt Cap22.09MTradable Cap20.90MTotal Shares8.09M
T/O32.39KT/O Rate0.16%Tradable Shares7.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

US Judge Consolidates Quantum BioPharma Stock-Manipulation Suits Against CIBC, RBC
Reuters  ·  10-08
US Judge Consolidates Quantum BioPharma Stock-Manipulation Suits Against CIBC, RBC
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
GlobeNewswire  ·  10-08
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
TIPRANKS  ·  10-08
Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
TIPRANKS  ·  10-07
Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial
TIPRANKS  ·  10-06
Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial
Quantum BioPharma Signs Thermo Fisher Clinical Research Unit Contract to Launch Phase 2 MS Trial
Reuters  ·  10-06
Quantum BioPharma Signs Thermo Fisher Clinical Research Unit Contract to Launch Phase 2 MS Trial
Quantum Biopharma - Thermo Fisher to Support Phase 2 Lucid-MS Clinical Trial Implementation
THOMSON REUTERS  ·  10-06
Quantum Biopharma - Thermo Fisher to Support Phase 2 Lucid-MS Clinical Trial Implementation
Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
TIPRANKS  ·  09-25
Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
Quantum BioPharma Licensee Unbuzzd Names Michael Zapolin CEO
Reuters  ·  09-24
Quantum BioPharma Licensee Unbuzzd Names Michael Zapolin CEO
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
GlobeNewswire  ·  09-24
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
TIPRANKS  ·  09-24
Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
Inside Quantum World Congress: Where FBI Agents, Big Tech, and Stock Hype Converge
Dow Jones  ·  09-24
Inside Quantum World Congress: Where FBI Agents, Big Tech, and Stock Hype Converge
Quantum BioPharma Board Authorizes Class a Multiple-Voting Share Offering to Lift Control Stake to 75.27%
Reuters  ·  09-18
Quantum BioPharma Board Authorizes Class a Multiple-Voting Share Offering to Lift Control Stake to 75.27%
Quantum BioPharma Plans Debt Conversion at Conversion Price of CAD 4 Per Share
Reuters  ·  09-18
Quantum BioPharma Plans Debt Conversion at Conversion Price of CAD 4 Per Share
Quantum BioPharma Grants 7,692 Stock Options to Director Zapolin at C$ 6.6 Per Share
Reuters  ·  09-18
Quantum BioPharma Grants 7,692 Stock Options to Director Zapolin at C$ 6.6 Per Share
Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
TIPRANKS  ·  09-18
Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
Rodman & Renshaw Initiates Quantum BioPharma Coverage with Buy Rating, US$ 8 Target
Reuters  ·  09-17
Rodman & Renshaw Initiates Quantum BioPharma Coverage with Buy Rating, US$ 8 Target
Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
TIPRANKS  ·  09-16
Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
GlobeNewswire  ·  09-15
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Stray Alert on Quantum BioPharma Withdrawn
Reuters  ·  09-14
Stray Alert on Quantum BioPharma Withdrawn

Introduction

Company Name.
Quantum Biopharma Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
Issue price:
--